Subscribe Us

header ads

Recents

header ads

Psoriasis Treatment Market Size At Around US$ 51.24 Bn In 2030

The psoriasis treatment market would grow at a CAGR of 8.16% over the predicted time frame. The market is expected to increase in value from US$ 27.36 Bn in 2022 to US$ 51.24 Bn in 2030.

Psoriasis Treatment Market Size 2022 To 2030

The on psoriasis treatment Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/2034

Report Scope of the Psoriasis Treatment Market

Report CoverageDetails
Market Size in 2022

USD 27.36 Billion

Market Size by 2030

USD 51.24 Billion

Growth Rate from 2022 to 2030CAGR of 8.16%
Base Year2021
Forecast Period2022 to 2030
Segments CoveredDrug Class, Treatment Type, Type, Route of Administration, Distribution Channel, Geography

A recent report provides crucial insights along with application based and forecast information in the Global Psoriasis treatment Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Psoriasis treatment market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Psoriasis treatment market are included as given below:

Psoriasis treatment Market Key Players

  • Johnson & Johnson Services, Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • LEO Pharma A/S (Denmark)
  • Merck & Co., Inc. (U.S.)
  • UCB S.A. (Belgium)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Amgen Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • Evelo Biosciences, Inc. (U.S.)

Market Segments

By Drug Class

  • Interleukins 
  • TNF Inhibitors
  • Others

By Treatment Type

  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies

By Type

  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Online pharmacies
  • Retail Pharmacies

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

Report Objectives

  • To define, describe, and forecast the global psoriasis treatment market based on product, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the psoriasis treatment market

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Psoriasis Treatment Market 

5.1. COVID-19 Landscape: Psoriasis Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Psoriasis Treatment Market, By Drug Class

8.1. Psoriasis Treatment Market, by Drug Class, 2022-2030

8.1.1. Interleukins

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. TNF Inhibitors

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Psoriasis Treatment Market, By Treatment Type

9.1. Psoriasis Treatment Market, by Treatment Type, 2022-2030

9.1.1. Biologic Drugs

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Small Molecule Systemic Drugs

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Tropical Therapies

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Psoriasis Treatment Market, By Type 

10.1. Psoriasis Treatment Market, by Type, 2022-2030

10.1.1. Psoriatic Arthritis

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Plaque Psoriasis

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Psoriasis Treatment Market, By Route of Administration

11.1. Psoriasis Treatment Market, by Route of Administration, 2022-2030

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Parenteral

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Topical

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Psoriasis Treatment Market, By Distribution Channel

12.1. Psoriasis Treatment Market, by Distribution Channel, 2022-2030

12.1.1. Hospital Pharmacies

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Online pharmacies

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Retail Pharmacies

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Psoriasis Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.3. Market Revenue and Forecast, by Type (2017-2030)

13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Type (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.7.  Rest of North America

13.1.7.1.  Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.1.7.3. Market Revenue and Forecast, by Type (2017-2030)

13.1.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.3. Market Revenue and Forecast, by Type (2017-2030)

13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Type (2017-2030)

13.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.7.  Germany

13.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.7.3.  Market Revenue and Forecast, by Type (2017-2030)

13.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.8.  France

13.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.8.3. Market Revenue and Forecast, by Type (2017-2030)

13.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.8.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.9. Rest of Europe

13.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Type (2017-2030)

13.2.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.9.5.  Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.3. Market Revenue and Forecast, by Type (2017-2030)

13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.6.  India

13.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Type (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.7. China

13.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.7.2.  Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.7.3. Market Revenue and Forecast, by Type (2017-2030)

13.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.8. Japan

13.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.8.2.  Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Type (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.3.9.3. Market Revenue and Forecast, by Type (2017-2030)

13.3.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.3. Market Revenue and Forecast, by Type (2017-2030)

13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.6.3.  Market Revenue and Forecast, by Type (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.7. North Africa

13.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.7.3. Market Revenue and Forecast, by Type (2017-2030)

13.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.8. South Africa

13.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Type (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.9. Rest of MEA

13.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.9.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.4.9.3. Market Revenue and Forecast, by Type (2017-2030)

13.4.9.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.9.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.  Latin America

13.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.3. Market Revenue and Forecast, by Type (2017-2030)

13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Type (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.7. Rest of LATAM

13.5.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.7.2. Market Revenue and Forecast, by Treatment Type (2017-2030)

13.5.7.3. Market Revenue and Forecast, by Type (2017-2030)

13.5.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 14. Company Profiles

14.1. Johnson & Johnson Services, Inc. (U.S.)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Pfizer Inc. (U.S.)

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. AbbVie Inc. (U.S.)

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Novartis AG (Switzerland)

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. LEO Pharma A/S (Denmark)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc. (U.S.)

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. UCB S.A. (Belgium)

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Sun Pharmaceutical Industries Ltd. (India)

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Amgen Inc. (U.S.)

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Eli Lilly and Company (U.S.)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 616

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

 

Post a Comment

0 Comments